tirzepatide for anti inflammatory GLP-1 drugs calm inflammation beyond diabetes and weight loss Frontiers | GLP-1/GIP dual agonist
Description
Use it within the assigned beyond-use date
The 60 mg vial costs more upfront than smaller sizes
A full list of clinical considerations for study discontinuation is provided in the online Supporting Information Appendix S1
N Engl J Med, 2022
Net-beneficial preferred terms uric acid lowered -0.69/-0.92/-0.95 mg/dL (about 73% mediated by weight loss)
The injectable formulation (tirzepatide/glycine/B12) is administered as a weekly subcutaneous injection and has more predictable bioavailability based on the extensive clinical trial data for injectable tirzepatide
